Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Monday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright lowered their price objective on shares of Aethlon Medical from $23.00 to $10.00 and set a buy rating on the stock in a research report on Monday, March 4th.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $1.25 on Monday. The stock has a market cap of $3.28 million, a price-to-earnings ratio of -0.25 and a beta of 1.95. Aethlon Medical has a 12 month low of $1.25 and a 12 month high of $5.00. The stock’s 50 day moving average price is $1.58 and its 200 day moving average price is $1.74.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.14). On average, sell-side analysts expect that Aethlon Medical will post -4.98 EPS for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.